Cimerli 0.3 mg/0.05 mL (6 mg/mL) intravitreal injection Images

Generic Name: ranibizumab

This medication has been identified as Cimerli 0.3 mg/0.05 mL (6 mg/mL) intravitreal injection. It is supplied by Coherus BioSciences, Inc.

Cimerli is used in the treatment of Macular Degeneration; Diabetic Retinopathy; Myopic Choroidal Neovascularization; Diabetic Macular Edema; Macular Edema and belongs to the drug class anti-angiogenic ophthalmic agents. Risk cannot be ruled out during pregnancy. Cimerli 0.3 mg/0.05 mL (6 mg/mL) intravitreal injection is not a controlled substance under the Controlled Substances Act (CSA).

Images of medication

Cimerli

Generic Name

ranibizumab

Strength

0.3 mg/0.05 mL (6 mg/mL) intravitreal injection

Availability

Prescription only

Drug Class

Anti-angiogenic ophthalmic agents

Pregnancy Category

C - Risk cannot be ruled out

CSA Schedule

Not a controlled drug

Labeler / Supplier

Coherus BioSciences, Inc.

National Drug Code (NDC)

70114-0440

Drug Uses Add to Drug List Print

Get help with Imprint Code FAQs.

See also:

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer